Views

CrossRef citations to date

Altmetric

Original Articles: Research

Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide

Rossana MaffeiDivision of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; View further author information

Stefania FiorcariDivision of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; View further author information

Silvia MartinelliDivision of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; View further author information

Stefania BenattiDivision of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; View further author information

Jenny BulgarelliDivision of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; ;Immunotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy; View further author information

Lara RizzottoDivision of Hematology Department of Biomedical Sciences, Azienda Ospedaliero-Universitaria Arcispedale S.Anna, University of Ferrara, Ferrara, Italy; View further author information

Giulia DebbiaDivision of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; View further author information

Rita SantachiaraDivision of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; View further author information

Gian Matteo RigolinDivision of Hematology Department of Biomedical Sciences, Azienda Ospedaliero-Universitaria Arcispedale S.Anna, University of Ferrara, Ferrara, Italy; View further author information

Francesco ForconiCancer Sciences Unit, CRUK Clinical Centre, University of Southampton, Southampton, UK; ;Division of Hematology, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy; View further author information

Davide RossiDepartment of Hematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland; ;Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy; View further author information

Luca LaurentiDepartment of Hematology, Catholic University of the Sacred Hearth, Rome, Italy; View further author information

Giuseppe A. PalumboDivision of Hematology, AOU “Policlinico- V. Emanuele”, Catania, Italy; View further author information

Daniele VallisaDepartment of Medical Oncology and Hematology, Hospital of Piacenza, Piacenza, ItalyView further author information

Antonio CuneoDivision of Hematology Department of Biomedical Sciences, Azienda Ospedaliero-Universitaria Arcispedale S.Anna, University of Ferrara, Ferrara, Italy; View further author information

Gianluca GaidanoDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy; View further author information

Mario LuppiDivision of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; View further author information

Roberto MarascaDivision of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; Correspondence[email protected]
View further author information

show all

Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Online Supplement Appendix

Supplemental Figure legends

Supplemental Figure 2

Supplemental Figure 1

Supplemental Table 5. Antibodies used in immunoblotting.

Supplemental Table 4. Flow cytometric stainings performed on samples collected from CLL patients before and after lenalidomide treatment.

Supplemental Table 3. List of antibodies used in flow cytometric evaluation of samples collected from CLL patients before and after lenalidomide treatment.

Supplemental Table 2. Characteristics of untreated CLL cohort#2 (n=30).

Supplemental Table 1. Prior therapies (n=26).

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Online Supplement Appendix

Supplemental Figure legends

Supplemental Figure 2

Supplemental Figure 1

Supplemental Table 5. Antibodies used in immunoblotting.

Supplemental Table 4. Flow cytometric stainings performed on samples collected from CLL patients before and after lenalidomide treatment.

Supplemental Table 3. List of antibodies used in flow cytometric evaluation of samples collected from CLL patients before and after lenalidomide treatment.

Supplemental Table 2. Characteristics of untreated CLL cohort#2 (n=30).

Supplemental Table 1. Prior therapies (n=26).

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date